Search Results for “Get instant Success With SAP C-C4H630-34 Exam Questions [2024] 🎯 Simply search for 【 C-C4H630-34 】 for free download on ➥ www.pdfvce.com 🡄 🏃Exam C-C4H630-34 Flashcards” – Page 35

The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change

297	Ertaş, R., Ozyurt, K., Atasoy, M., Hawro, T., and Maurer, M.+: The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change. Allergy 2018: 73; 705-712. IF: 6.77

100	Dölle, S., Hoser, D., Rasche, C., Loddenkemper, C., Maurer, M. Zuberbier, T., and Worm, M.+: Long-term reduction in local inflammation by a lipid raft molecule in atopic dermatitis. Allergy 2010: 65; 1158-1165. IF: 6.29

Impaired T-cell-dependent protection against Leishmania major infection in HIV-positive patients is associated with worsened disease outcome

207

Ngouateu, O. B., Weller, K., Bröhl, K., Kamtchouing, P., Same-Ekobo, A., Dondji, B. , Maurer, M., and Stebut, E.+: Impaired T cell-dependent protection against Leishmania major infection in HIV-positive patients is associated with worsened disease outcome. Exp. Dermatol. 2015: 24; 302-304. IF: 2.67

o.207

16.	Maurer, M.: Chronic urticaria. In: Zuberbier, T. Grattan, C., and Maurer, M., editors: Urticaria and Angioedema. Heidelberg: Springer, 2010

108	Franzke, N.+, Schäfer, I., Jost, K., Blome, C., Rustenbach, S. J., Reich, K., Reusch, M., Maurer, M. and Augustin, M.: A new instrument for the assessment of patient-defined benefit in the treatment of allergic rhinitis. Allergy 2011: 66; 665-670. IF: 6.27

Innate immunity in atopic dermatitis

17.

Mrabet-Dahbi, S. and Maurer, M.: Innate immunity in atopic dermatitis. In: Shiohara T., Amagai, M., Homey, B., Nakanishi, K., Woodfolk, J. A., Bieber, T., Flohr, C., Schittek, B., Hayakawa, J., Yu, H.-S., Oranje, A. P., Schmid-Grendelmeier, P., and Akdis, C. A., editors: Current Problems in Dermatology „Atopic Dermatitis“. Basel: S. Karger Publishers, 2011

386.	Chen, Y.-D., Krause, K., Tu, P., Zhao, Z.⁺, and Maurer, M.⁺: Response of omalizumab in normocomplementemic urticarial vasculitis. J. Allergy Clin. Immunol. Pract. 2020: 8; 2114-2117. IF: 8.86

o.386

345	Krause, K., Sabat, R., Witte-Händel, E., Schulze, A., Puhl, V., Maurer, M., and Wolk, K.+: Association of CCL2 with systematic inflammation in Schnitzler syndrome. Br. J. Dermatol. 2019: 180; 859-868. IF: TBD (IF 2018: 6.71)

Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background Therapy

211

Casale, T. B., Bernstein, J. A., Maurer, M. Saini, S. S., Trzaskoma, B., Chen, H., Grattan, C., Gimenèz-Arnau, A., Kaplan, A. P., and Rosén, K.+: Similar efficacy with Omalizumab in chronic idiopathic/spontaneous urticaria despite different background therapy. J. Allergy Clin. Immunol. Pract. 2015: 3; 743-750. IF: 5.42

Turkish version of the chronic urticaria quality of life questionnaire: cultural adaption, assessment of reliability and validity

134

Kocatürk, E.+, Weller, K., Martus, P., Aktas, S., Kavala, M., Sarigul, S., Baiardini, I., Canonica, G. W., Brzoza, Z., Kalogeromitros, and Maurer, M.: Turkish version of the chronic urticaria quality of life questionnaire: cultural adaption, assessment of reliability and validity. Acta Derm. Venereol. 2012: 92; 419-425. IF: 3.48

o.134

Results